MCE - Delayed Quote • EUR
Clínica Baviera, S.A. (CBAV.MC)
At close: April 24 at 3:35 PM GMT+2
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2022) | Next Qtr. (Dec 2022) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | -- |
| Avg. Estimate | 0 | 0 | 1.8 | 0 |
| Low Estimate | 0 | 0 | 1.8 | 0 |
| High Estimate | 0 | 0 | 1.8 | 0 |
| Year Ago EPS | -- | -- | -- | 1.8 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2022) | Next Qtr. (Dec 2022) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | -- | -- | 190M | 202M |
| Low Estimate | -- | -- | 190M | 202M |
| High Estimate | -- | -- | 190M | 202M |
| Year Ago Sales | -- | -- | -- | 190M |
| Sales Growth (year/est) | -- | -- | -- | 6.30% |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2022) | Next Qtr. (Dec 2022) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 1.8 | 0 |
| 7 Days Ago | 0 | 0 | 1.8 | 1.76 |
| 30 Days Ago | 0 | 0 | 1.62 | 1.76 |
| 60 Days Ago | 0 | 0 | 1.62 | 1.76 |
| 90 Days Ago | 0 | 0 | 1.62 | 1.76 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2022) | Next Qtr. (Dec 2022) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CBAV.MC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 1.50% |
| Next Qtr. | -- | -- | -- | 11.40% |
| Current Year | -- | -- | -- | 5.20% |
| Next Year | -- | -- | -- | 13.40% |
| Next 5 Years (per annum) | 12.20% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 0.00% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
No Fair Value available for this ticker